News

Enlarge image

PolicyBelgiumEUGermanyItalyUKFinland

Biofuels producers join forces

11.02.2013 - Seven leading producers of second generation biofuels have joined forces in an industry initiative to support uptake of their technology.

The initiative, named “Leaders of Sustainable Biofuels”, aims at supporting the development of second generation biofuels as a sustainable alternative to fossil fuels in Europe. The leaders of Chemtex, British Airways, BTG, Chemrec, Clariant, Dong Energy and UPM are joining forces to ensure the market uptake of advanced sustainable biofuels by all transport sectors. The Chief Executive Officers of the companies suggested biofuels were cost-competitive and had less environmental impact than fuels made from oil or natural gas. They argue that second-generation biofuels can reduce GHG emissions by at least 65%.

In contrast, first generation biofuels, made from corn, wheat, soy or palm provide only modest reductions in greenhouse gases and can push up food prices. At the initiative’s launch in Brussels, the “Leaders of Sustainable Biofuels” demanded to accelerate research and innovation into emerging biofuel technologies, including algae and new conversion pathways, supported by public and private R&D programmes. They said it were important to develop worldwide accepted sustainability certification and to establish financing structures to facilitate the implementation of sustainable biofuel projects. The initiative aims at promoting the benefits of advanced sustainable biofuels and to address national policy makers, the European Commission and the European Parliament. The “Leaders are convinced that their biofuels are key for the reduction of fossil energy imports in the EU”. 

© eurobiotechnews.eu/tg 

http://www.european-biotechnology-news.com/news/news/2013-01/biofuels-producers-join-forces.html

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. However, a preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

M&AFinland

19.01.2016 Biotie Therapies has long been expanding its business in the US. Now, the Finnish company is set to be taken over by US company Acorda Therapeutics, which is paying €321m for the shares.

Drug AssessmentPortugalFrance

18.01.2016 A Phase I clinical trial for a drug developed by Portuguese pharma company Bial has ended in disaster. One man died, five others may have irreversible neurological damage.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MAGFORCE (D)5.25 EUR5.00%
  • SCANCELL HOLDINGS (UK)18.25 GBP4.29%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • IMMUPHARMA (UK)25.50 GBP-12.07%

TOP

  • EPIGENOMICS (D)4.46 EUR109.4%
  • VERONA PHARMA (UK)3.40 GBP28.3%
  • WILEX (D)2.09 EUR19.4%

FLOP

  • PROTHENA PLC (IE)34.27 USD-39.1%
  • PLETHORA (UK)2.75 GBP-33.3%
  • BIONOR PHARMA (N)0.88 NOK-30.2%

TOP

  • KARO BIO (S)26.80 SEK3728.6%
  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • 4SC (D)3.33 EUR291.8%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.80 SEK-85.6%
  • BIOTEST (D)14.11 EUR-84.5%
  • EVOCUTIS (UK)0.08 GBP-71.4%

No liability assumed, Date: 06.02.2016